Deficiency of Orexin Receptor Type 1 in Dopaminergic Neurons Increases Novelty-Induced Locomotion and Exploration

  1. Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Gleueler Strasse 50, 50931 Cologne, Germany
  2. Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Joseph-Stelzmann-Strasse 26, 50931 Cologne, Germany
  3. Department of Biology, Institute for Zoology, University of Cologne, Zülpicher Strasse 47b, 50674 Cologne, Germany
  4. Max Planck Institute for Metabolism Research, Multimodal Imaging of Brain Metabolism Group, Gleueler Strasse 50, 50931 Cologne, Germany

Peer review process

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews.

Read more about eLife’s peer review process.

Editors

  • Reviewing Editor
    Laura Bradfield
    University of Technology Sydney, Sydney, Australia
  • Senior Editor
    Kate Wassum
    University of California, Los Angeles, Los Angeles, United States of America

Reviewer #1 (Public Review):

Summary:
In this manuscript, the role of orexin receptors in dopamine neurons is studied. Considering the importance of both orexin and dopamine signalling in the brain, with critical roles in arousal and drug seeking, this study is important to understand the anatomical and functional interaction between these two neuromodulators. This work suggests that such interaction is direct and occurs at the level of SN and VTA, via the expression of OX1R-type orexin receptors by dopaminergic neurons.

Strengths:
The use of a transgenic line that lacks OX1R in dopamine-transporter-expressing neurons is a strong approach to dissecting the direct role of orexin in modulating dopamine signalling in the brain. The battery of behavioural assays to study this line provides a valuable source of information for researchers interested in the role of orexin-A in animal physiology.

Weaknesses:
The choice of methods to demonstrate the role of orexin in the activation of dopamine neurons is not justified and the quantification methods are not described with enough detail. The representation of results can be dramatically improved and the data can be statistically analysed with more appropriate methods.

Reviewer #2 (Public Review):

Summary:
This manuscript examines the expression of orexin receptors in the midbrain - with a focus on dopamine neurons - and uses several fairly sophisticated manipulation techniques to explore the role of this peptide neurotransmitter in reward-related behaviors. Specifically, in situ hybridization is used to show that dopamine neurons predominantly express the orexin receptor 1 subtype and then go on to delete this receptor in dopamine neurons using a transgenic strategy. Ex vivo calcium imaging of midbrain neurons is used to show that in the absence of this receptor orexin is no longer able to excite dopamine neurons of the substantia nigra.

The authors proceed to use this same model to study the effect of orexin receptor 1 deletion on a series of behavioral tests, namely, novelty-induced locomotion and exploration, anxiety-related behavior, preference for sweet solutions, cocaine-induced conditioned place preference, and energy metabolism. Of these, the most consistent effects are seen in the tests of novelty-induced locomotion and exploration in which the mice with orexin 1 receptor deletion are observed to show greater levels of exploration, relative to wild-type, when placed in a novel environment, an effect that is augmented after icv administration of orexin.

In the final part of the paper, the authors use PET imaging to compare brain-wide activity patterns in the mutant mice compared to wildtype. They find differences in several areas both under control conditions (i.e., after injection of saline) as well as after injection of orexin. They focus on changes in the dorsal bed nucleus of stria terminalis (dBNST) and the lateral paragigantocellular nucleus (LPGi) and perform analysis of the dopaminergic projections to these areas. They provide anatomical evidence that these regions are innervated by dopamine fibers from the midbrain, are activated by orexin in control, but not mutant mice, and that dopamine receptors are present. Thus, they argue these anatomical data support the hypothesis that behavioral effects of orexin receptor 1 deletion in dopamine neurons are due to changes in dopamine signaling in these areas.

Strengths:
Understanding how orexin interacts with the dopamine system is an important question and this paper contains several novel findings along these lines. Specifically:
(1) The distribution of orexin receptor subtypes in VTA and SN is explored thoroughly.
(2) Use of the genetic model that knocks out a specific orexin receptor subtype from only dopamine neurons is a useful model and helps to narrow down the behavioral significance of this interaction.
(3) PET studies showing how central administration of orexin evokes dopamine release across the brain is intriguing, especially since two key areas are pursued - BNST and LPGi - where the dopamine projection is not as well described/understood.

Weaknesses:
The role of the orexin-dopamine interaction is not explored in enough detail. The manuscript presents several related findings, but the combination of anatomy and manipulation studies does not quite tell a cogent story. Ideally, one would like to see the authors focus on a specific behavioral parameter and show that one of their final target areas (dBNST or LPGi) was responsible or at least correlated with this behavioral readout. In addition, some more discussion on what the results tell us about orexin signaling to dopamine neurons under normal physiological conditions would be very useful. For example, what is the relevance of the orexin-dopamine interaction blunting novelty-induced locomotion under wildtype conditions?

In some places in the Results, insufficient explanation and reporting is provided. For example, when reporting the behavioral effects of the Ox1 deletion in two bottle preference, it is stated that "[mutant] mice showed significant changes..." without stating the direction in which preference was affected.

The cocaine CPP results are difficult to interpret because it is unclear whether any of the control mice developed a CPP preference. Therefore, it is difficult to conclude that the knockout animals were unaffected by drug reward learning. Similarly, the sucrose/sucralose preference scores are also difficult to interpret because no test of preference vs. water is performed (although the data appear to show that there is a preference at least at higher concentrations, it has not been tested).

  1. Howard Hughes Medical Institute
  2. Wellcome Trust
  3. Max-Planck-Gesellschaft
  4. Knut and Alice Wallenberg Foundation